Skip to main
ELV

ELV Stock Forecast & Price Target

ELV Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 35%
Buy 35%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

Elevance Health is in a strong financial position, with a positive outlook for growth in its Medicaid and Medicare Advantage plans and the potential for expansion into pharmacy benefit management and other healthcare services. The company's recent acquisitions, strong position as the largest single provider for Blue Cross Blue Shield branded coverage, and diversified coverage plans make it a leader in the health insurance industry. In addition, the company's commitment to diversity within its leadership and workforce, along with its efforts to address social responsibility issues in its communities, make it a strong choice for sustainability-oriented investors. While there may be some concerns about rising costs and potential challenges in the commercial market, we believe Elevance's strong overall performance, growth opportunities, and sound financials make it a solid investment choice.

Bears say

Elevance Health is a leading health insurance company in the US with a unique position as the largest single provider of Blue Cross Blue Shield branded coverage in 14 states. However, the company faces potential risks such as incremental risk pool deterioration in the ACA market, Medicaid cost utilization spikes, and lack of uptake of its Carelon services. While management has a commitment to grow EPS by at least 12% in 2027, there are uncertainties and risks that may hinder this goal. Additionally, the company's 2026 EPS guidance and margin projections are lower compared to previous estimates.

ELV has been analyzed by 20 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 35% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elevance Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elevance Health Inc (ELV) Forecast

Analysts have given ELV a Buy based on their latest research and market trends.

According to 20 analysts, ELV has a Buy consensus rating as of Aug 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $437.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $437.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elevance Health Inc (ELV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.